NANTES, France, Sept. 6, 2016 (GLOBE NEWSWIRE) -- OGD2 Pharma SAS, a biotechnology company developing innovative anti-cancer therapies targeting the O-acetylated form of the GD2 ganglioside (OAcGD2), today announces a collaboration with Syndivia SAS, a biotechnology company that provides best-in-class bioconjugation technologies for the development of Antibody-Drug Conjugates (ADC).

This collaboration agreement will explore the potential of targeting chemotherapeutic drugs using anti-OAcGD2 ADCs in the treatment of difficult-to-treat solid tumors. The ADCs will be designed to release the cytotoxic drug both within tumor cells and in the tumor microenvironment.

"Thanks to this collaboration, OGD2 Pharma accelerates the development of its anti-OAcGD2 ADC platform. Syndivia's versatile linker technology will allow depicting the best way to specifically deliver ADC payloads to tumors using the unique cellular biology of the OAcGD2 membrane glycolipid" said Jean-Marc Le Doussal, President at OGD2 Pharma. "Syndivia's technology should result in ADCs that are highly stable in patient's blood, in line with our strategy to develop safer anti-cancer therapies leveraging the highly tumor-specific tissue distribution of the OAcGD2 antigen. OGD2 Pharma will continue building such strategic partnerships with academic groups and private companies in other ADC technologies." he added.

Oleksandr Koniev, Chief Executive Officer of Syndivia commented "We are excited by this synergy between Syndivia's stable payloads for intracellular and tumor microenvironment specific drug release and OGD2 Pharma's innovative immunotherapy agents targeting OAcGD2 antigen. We believe this collaboration will result in the development and future commercialization of a brand-new class of efficient ADC for unmet clinical needs in both pediatric and adult cancers".

About Syndivia: www.syndivia.com

Syndivia SAS, headquartered in Illkirch, France, is a biotechnology company providing best-in-class bioconjugation technologies for the development of Antibody-Drug Conjugates (ADC). With a strong portfolio of patented ADC payloads and know-how in ADC preparation and characterization Syndivia is building up a strong partnered pipeline of ADCs for a broad range of oncology indications.

About OGD2 Pharma: www.ogd2pharma.com

OGD2 Pharma SAS, headquartered in Nantes, France, is a pre-clinical stage privately-held biotechnology company. Our mission is to research, develop and commercialize, with pharmaceutical partners, safe and efficacious cancer immunotherapies targeting the O-acetylated form of the GD2 ganglioside (OAcGD2). Pipeline includes OGD201 humanized monoclonal antibody (EMA Orphan Drug Designation for neuroblastoma), chimeric antigen receptors (CAR), antibody drug conjugates and companion diagnostic products.

About O-acetylated-GD2

As its first cousin GD2, the OAcGD2 glycolipid is expressed at high copy numbers in the membrane of tumor cells in many types of pediatric cancers (such as neuroblastoma) and adult cancers (such as glioblastoma, melanoma, sarcoma, breast cancer, etc.) and on cancer stem cells. Remarkably, and by contrast to GD2, OAcGD2 is not expressed by normal nerves and brain tissues.

About APN and C&R Technology

Syndivia's APN technology enable the preparation of ADCs having increased stability in blood circulation. This stability is of crucial importance for oncology applications as it widens the therapeutic index of the conjugates. The C&R technology allows for tumor-specific release of the cytotoxic payload both inside cancer cells and in tumor microenvironment. This tumor-specific release contributes further to the improvement of the efficacy and toxicity profile of Syndivia's ADCs.

Contacts: OGD2 Pharma

Business Development                               
Farid Bouzidi    
bouzidi@ogd2pharma.com      

Alliance Management                   
Samuel Salot                                     
salot@ogd2pharma.com             

Enregistrer

OGD2 Pharma and Syndivia launch collaboration to develop an ADC http://hugin.info/172779/R/2039775/760485.pdf